| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 95.78 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Polyglutamine (polyQ) diseases are a group of rare neurodegenerative disorders that
share a common genetic cause: they arise as a result of abnormal expansions of
CAG trinucleotide sequences occurring at particular genome loci. In contrast with
other repeat-related disorders, the repeat-bearing tracts associated with polyQ diseases are present at the codifying region of genes, being translated as expanded
polyQ tracts in their respective protein products. Although these genes and proteins
are otherwise unrelated and share no significant homology outside the CAG/polyQ
tract, proteins carrying an abnormally expanded polyQ tract tend to aggregate,
forming insoluble protein aggregates that constitute a key neuropathological feature
of polyQ disorders. The group currently includes nine disorders: Huntington’s
disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinal and bulbar
muscular atrophy (SBMA), and six different types of spinocerebellar ataxia: SCA 1,
2, 3, 6, 7, and 17. PolyQ diseases are highly incapacitating and, to this date, no
therapy able to modify disease progression is available for any of them.
Description
Keywords
Citation
Publisher
Springer Verlag